{
    "pmcid": "10054972",
    "qa_pairs": {
        "What method was used to map the epitopes recognized by the nanobodies?": [
            "Peptide arrays and competition assays",
            "X-ray crystallography and NMR spectroscopy",
            "Western blotting and ELISA",
            "Flow cytometry and mass spectrometry"
        ],
        "What strategy does the study suggest for enhancing the neutralization potency and breadth of nanobodies?": [
            "Engineering multivalent nanobodies or cocktails",
            "Increasing the dosage of a single nanobody",
            "Targeting only the S2 subunit of the Spike protein",
            "Focusing exclusively on linear epitopes"
        ],
        "What was a notable feature of the nanobodies' ability to reduce viral load in mice?": [
            "Their ability to cross the blood-brain barrier",
            "Their ability to be administered intravenously",
            "Their ability to target the nucleocapsid protein",
            "Their ability to inhibit viral RNA replication"
        ],
        "What was the primary target for neutralizing antibodies in the study on llama-derived nanobodies against SARS-CoV-2?": [
            "The receptor binding domain (RBD) of the Spike protein",
            "The S2 subunit of the Spike protein",
            "The nucleocapsid protein of the virus",
            "The membrane protein of the virus"
        ],
        "Which variants of SARS-CoV-2 were the llama-derived nanobodies shown to neutralize?": [
            "Alpha, Beta, Delta, and Omicron",
            "Gamma, Lambda, Mu, and Epsilon",
            "Zeta, Eta, Theta, and Iota",
            "Kappa, Nu, Xi, and Rho"
        ]
    }
}